TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02866396

Intervention type: DRUG
Intervention: Pregabalin
Description: Pregabalin continued at the same preoperative dose 1h before surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS \> 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS\>3

Intervention type: OTHER
Intervention: Naive patient
Description: Pregabalin 150mg PO initiated 1h before surgery Associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS \> 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS\>3
Study: NCT02418715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Aerobics Training
Study: NCT01470599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: ORAL TABLET, TWICE DAILY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: ORAL TABLETS, TWICE DAILY
Study: NCT03238222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOSAIC
Description: MOSAIC comprises 2 x 60-minute individual face-to-face consultations (weeks 1 \& 2) and 2 x 20-minute follow-up telephone calls (weeks 6 \& 12) delivered at a convenient time and location of participant's choice (local NHS Trust or participant's home). All sessions are delivered by a trained Band 6/7 physiotherapist. All participants randomized to receive MOSAIC will be provided with a pedometer and a patient manual which will include information on intermittent claudication, risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.
Study: NCT00624013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: 50 mg up to 100 mg daily for 6 months
Study: NCT03920423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: improvement of arterial depth
Description: deepen radial arterial depth by injection of saline to more than deep cutoff point relative to result.
Study: NCT03120494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine and Tenofovir
Description: All subjects will be provided study drug for use daily for one year.
Study: NCT00624013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg up to 100 mg daily for 6 months
Study: NCT04608136

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet intervention
Description: Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
Study: NCT01852032

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomosynthesis Breast Scanning
Description: The breast is positioned and compressed the same way it is in a conventional mammogram using a compression paddle device. The subject will be instructed to hold their breath and not move during the 7- second 3-D tomosynthesis acquisition. The affected breast is positioned with MLO compression. The radiation dose levels for each scan are equivalent to mammography

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Breast CT Scanning
Description: CT scanning will be performed before and after I.V. iodine contrast injection. The subject will lie prone on a large table (which is covered by a foam pad), and she will place the breast to be scanned in a small hole in that tabletop. The hole is surrounded by a soft neoprene hammock, which will allow the subject's entire upper torso to slump into the scan plane of the device. After positioning of the affected breast by a female mammography technologist, the subject will be instructed to hold their breath for 16 seconds and the pre-contrast scan will commence. There will be no breast compression. Other than the sound of the relatively noisy x-ray system in the room, the subject will not feel or sense any aspect of this scan.
Study: NCT01501409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium lauryl sulfate
Description: The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group I used SLS-free(a commercially available SLS-free dentifrice(Wiconi® dentifrice) and SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium lauryl sulfate
Description: The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group II used SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS) and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium lauryl sulfate
Description: The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group III used SLS-free (a commercially available SLS-free dentifrice (Wiconi® dentifrice), and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
Study: NCT01610960

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation HELMET
Description: The HELMET and HELMET NEXT modes will be tested by each patient.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non invasive ventilation facemask (Respironics)
Description: The facemask Respironics (Herrsching, Germany) will be used by each patient.
Study: NCT02787811

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemenation
Description: Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemenation
Description: Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation
Study: NCT04241809

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioaerosol Sampling
Description: Cyclone collection of exhaled bioaerosol

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioaerosol Sampling
Description: Cyclone collection of exhaled bioaerosol

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioaerosol Sampling
Description: Cyclone collection of exhaled bioaerosol
Study: NCT04418661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442720
Description: Pharmaceutical form: Varies Route of administration: Varies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442720
Description: Pharmaceutical form: Varies Route of administration: Varies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442720
Description: Pharmaceutical form: Varies Route of administration: Varies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442720
Description: Pharmaceutical form: Varies Route of administration: Varies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442720
Description: Pharmaceutical form: Varies Route of administration: Varies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442720
Description: Pharmaceutical form: Varies Route of administration: Varies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form:Sterile Lyophilized powder for reconstitution Route of administration: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form:Sterile Lyophilized powder for reconstitution Route of administration: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form:Sterile Lyophilized powder for reconstitution Route of administration: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form:Sterile Lyophilized powder for reconstitution Route of administration: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Pharmaceutical form:Sterile Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Pharmaceutical form:Sterile Tablet Route of administration: Oral
Study: NCT01547117

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Blood Volume
Description: we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Blood Volume
Description: we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Blood Volume
Description: Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Blood Volume
Description: Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Capacity Test - Bicycle
Description: subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Capacity Test - Bicycle
Description: subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posture Study
Description: Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posture Study
Description: Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
Study: NCT04815343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Naída CI M90 Sound Processor (hearing aid and cochlea implant sound processor)
Description: Speech perception measures, Hearing thresholds, Enjoyment rating, Sound identification, Subjective feedback

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Naída CI M90 Sound Processor (hearing aid and cochlea implant sound processor)
Description: Speech perception measures, Hearing thresholds, Enjoyment rating, Sound identification, Subjective feedback
Study: NCT02830048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Study: NCT04026399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peripheral vibration stimulation
Description: wearing a wristband that delivers imperceptible vibratory stimulation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: therapy
Description: practice of daily living tasks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapy
Description: practice of daily living tasks
Study: NCT02431455

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incentive spirometer
Description: Incentive spirometer is provided to the patient, this is the current standard of care, and is the control arm.
Study: NCT04303468

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GABA
Description: The dietary supplement GABA will be taken orally 3 times daily, before each main meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsule containing powdered cellulose
Study: NCT01022216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procellera™ Wound Dressing with V.A.C.® Therapy
Description: Dressing indicated for partial and full-thickness wounds. Weekly dressing changes, more frequently if needed. Used as a primary contact layer in conjunction with NPWT.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V.A.C.® Therapy
Description: Vacuum Assisted Closure device that uses controlled negative pressure, with dressing changes 1x/week.
Study: NCT03905681

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Application of TENS pads and wearing of the TENS device.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Application of TENS pads and wearing of the TENS device.
Study: NCT02814617

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cordyceps sinensis mycelium culture extract 1.68 g
Description: Cordyceps sinensis mycelium culture extract 1.68 g

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03661216

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nephure Oxalate-reducing Enzyme
Description: 3g of Nephure is mixed with 8oz of water and ingested with breakfast, lunch and dinner.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g of non-GMO maltodextrin is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
Study: NCT02454868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil for intubation without neuromuscular blockade
Study: NCT00999700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel - cisplatin - 5-fluorouracil
Description: docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated.
Study: NCT04274309

Intervention type: DEVICE
Intervention: EndoSWIR
Description: Exposition of the respected tissues to the camera

Intervention type: DEVICE
Intervention: EndoSWIR
Description: Exposition of the respected tissues to the camera
Study: NCT01777737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Description: 24 weeks of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical capsules to cotrimoxazole
Study: NCT00743678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6/cetuximab
Description: Neoadjuvant FOLFOX6/cetuximab
Study: NCT03958942

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound quadratus lumborum block with bupivacaine 25%
Description: echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lumbar epideural block with bupivacaine 25%
Description: lumbar epidural will be performed for patients in group II using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces will be chosen for the injection. The epidural space identified by the loss of resistance technique.
Study: NCT03178851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab, 840 mg intravenously every two weeks (Q2W) on Days 1 and 15 of each 28-day cycle, until loss of clinical benefit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib, 60 mg orally once daily (QD) on Days 1-21 of each 28-day cycle, until loss of clinical benefit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib, 60 mg orally once daily (QD) on Days 1-21 of each 28-day cycle, until loss of clinical benefit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab, 840 mg intravenously on Day 15 of Cycle 1; thereafter Q2W on Days 1 and 15 of Cycle 2 and all subsequent 28-day cycles, until loss of clinical benefit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab, 1200 mg intravenously every three weeks (Q3W) on Day 1 of each 21-day cycle, until loss of clinical benefit
Study: NCT00581425

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imiquimod and Interferon alpha
Description: Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
Study: NCT04365075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer Laser Combined with DCB
Description: Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty Alone
Description: Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.
Study: NCT02727309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib: 750 mg is administered orally daily, until disease progression or untolerable toxicity.
Study: NCT02313805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist
Description: The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are on the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
Study: NCT02431455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No incentive spirometer
Description: No incentive spirometer is provided to the patient, this is the study arm.
Study: NCT00002796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indomethacin
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon gamma
Description: Given subcutaneously
Study: NCT03871621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Medicines
Description: Anti-diabetic medications except SGLT2 inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Medicines
Description: Anti-diabetic medications except SGLT2 inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin tablet (10 mg)
Study: NCT02168283

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: treatment arm
Description: Hypertonic peritoneal dialysis cycles

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: Dietary counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control arm
Description: Dietary counseling
Study: NCT03139305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Low dose intravenous infusion for 72 hours at 12.5 ng/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: High dose intravenous infusion for 72 hours at 25 ng/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of saline for 72 hours